PH12014500094A1 - Combination als therapy - Google Patents

Combination als therapy

Info

Publication number
PH12014500094A1
PH12014500094A1 PH1/2014/500094A PH12014500094A PH12014500094A1 PH 12014500094 A1 PH12014500094 A1 PH 12014500094A1 PH 12014500094 A PH12014500094 A PH 12014500094A PH 12014500094 A1 PH12014500094 A1 PH 12014500094A1
Authority
PH
Philippines
Prior art keywords
riluzole
subject
methods
reducing
combination
Prior art date
Application number
PH1/2014/500094A
Other languages
English (en)
Inventor
Jesse Cedarbaum
Fady Malik
John Mao
Andrew A Wolff
Original Assignee
Cytokinetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytokinetics Inc filed Critical Cytokinetics Inc
Publication of PH12014500094A1 publication Critical patent/PH12014500094A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PH1/2014/500094A 2011-07-13 2012-07-12 Combination als therapy PH12014500094A1 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201161507381P 2011-07-13 2011-07-13
US201161544533P 2011-10-07 2011-10-07
US201261637770P 2012-04-24 2012-04-24
US201261637759P 2012-04-24 2012-04-24
US201261646699P 2012-05-14 2012-05-14
PCT/US2012/046523 WO2013010015A2 (en) 2011-07-13 2012-07-12 Combination als therapy

Publications (1)

Publication Number Publication Date
PH12014500094A1 true PH12014500094A1 (en) 2014-03-17

Family

ID=47506929

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2014/500094A PH12014500094A1 (en) 2011-07-13 2012-07-12 Combination als therapy

Country Status (16)

Country Link
US (1) US10272082B2 (enExample)
EP (1) EP2731611B1 (enExample)
JP (2) JP6145946B2 (enExample)
KR (1) KR101951220B1 (enExample)
CN (2) CN104039148A (enExample)
AU (2) AU2012281042B2 (enExample)
BR (1) BR112014000742A2 (enExample)
CA (1) CA2849213A1 (enExample)
EA (2) EA028060B1 (enExample)
HK (1) HK1197178A1 (enExample)
IL (1) IL230391B (enExample)
IN (1) IN2014DN00200A (enExample)
PH (1) PH12014500094A1 (enExample)
SG (1) SG10201605707UA (enExample)
WO (1) WO2013010015A2 (enExample)
ZA (1) ZA201400236B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8299248B2 (en) 2006-08-02 2012-10-30 Cytokinetics, Incorporated Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
US20160263110A1 (en) * 2013-11-04 2016-09-15 Ab Science Use of masitinib for treatment of amyotrophic lateral sclerosis
EP3137622B1 (en) * 2014-04-29 2021-11-24 Cytokinetics, Inc. Methods of reducing decline in vital capacity
EA201791110A1 (ru) * 2014-11-21 2017-11-30 Биохэвен Фармасьютикэл Холдинг Компани Лтд. Сублингвальное введение рилузола
LT3220891T (lt) 2014-11-21 2019-11-11 Biohaven Therapeutics Ltd Poliežuvinė riluzolio kompozicija
EP3072513A1 (en) * 2015-03-26 2016-09-28 Medday Biotin for treating Amyotrophic lateral sclerosis
SG11201808106YA (en) 2016-03-25 2018-10-30 Ab Science Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation
EP4031135A4 (en) 2019-09-20 2023-10-18 Icahn School of Medicine at Mount Sinai CONTROLLED RELEASE FORMULATIONS OF RILUZOLE AND USES THEREOF

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3507866A (en) 1967-08-08 1970-04-21 Merck & Co Inc 1h - imidazo(4,5-b)pyrazin - 2 - one and processes for their preparation
BE788065A (fr) 1971-08-26 1973-02-26 Degussa Nouvelles aza-benzimidazoles et procede pour leur preparation
IT1156732B (it) 1978-05-10 1987-02-04 Roussel Maestretti Spa Derivati sostituiti dell'1,3-diidroimidazo(4,5-b)piridin-2-one e relativo procedimento di produzione
US4668686A (en) 1985-04-25 1987-05-26 Bristol-Myers Company Imidazoquinoline antithrombrogenic cardiotonic agents
US4775674A (en) 1986-05-23 1988-10-04 Bristol-Myers Company Imidazoquinolinylether derivatives useful as phosphodiesterase and blood aggregation inhibitors
US4943573A (en) 1989-11-01 1990-07-24 Bristol-Myers Squibb Company Imidazo[4,5-b]quinolinyloxyalkanoic acid amides with enhanced water solubility
US5354759A (en) 1991-09-12 1994-10-11 Fujisawa Pharmaceutical Co., Ltd. Angiotenin II antagonizing heterocyclic compounds
JPH0641135A (ja) 1992-07-21 1994-02-15 Nippon Soda Co Ltd イミダゾプテリジン誘導体及びその製造方法
US6162804A (en) 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
IL139811A0 (en) 1998-06-04 2002-02-10 Abbott Lab Cell adhesion-inhibiting antinflammatory compounds
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
EP1218383B1 (de) 1999-10-08 2008-11-05 Grünenthal GmbH Bicyclische imidazo-5-yl-aminderivate
AU779197B2 (en) 1999-10-08 2005-01-13 Grunenthal Gmbh Bicyclic imidazo-3-yl-amine derivatives
DE10050663A1 (de) 2000-10-13 2002-04-18 Gruenenthal Gmbh Verwendung von substituierten Imidazo[1,2-a]pyridin-, -pyrimidin- und pyrazin-3-yl-amin-Derivaten zur Herstellung von Medikamenten zur NOS-Inhibierung
US20030083318A1 (en) * 2001-10-25 2003-05-01 Jean-Pierre Julien Therapy for neurodegenerative diseases
US20040235801A1 (en) * 2001-10-25 2004-11-25 Jean-Pierre Julien Therapy for stroke
GB0206860D0 (en) 2002-03-22 2002-05-01 Glaxo Group Ltd Compounds
GB0212048D0 (en) 2002-05-24 2002-07-03 Merck Sharp & Dohme Therapeutic agents
AU2003294249A1 (en) 2002-11-08 2004-06-03 Trimeris, Inc. Hetero-substituted benzimidazole compounds and antiviral uses thereof
GB2400101A (en) 2003-03-28 2004-10-06 Biofocus Discovery Ltd Compounds capable of binding to the active site of protein kinases
JO2355B1 (en) 2003-04-15 2006-12-12 ميرك شارب اند دوم كوربوريشن Hereditary calcitonin polypeptide receptor antagonists
US7476665B2 (en) 2003-06-26 2009-01-13 Merck & Co., Inc. Benzodiazepine CGRP receptor antagonists
US20060148805A1 (en) 2003-07-01 2006-07-06 Meng Hsin Chen Opthalmic compositions for treating ocular hypertension
CA2550091A1 (en) 2003-12-19 2005-07-07 Elixir Pharmaceuticals, Inc. Methods of treating a disorder
EP1715855A4 (en) 2004-01-29 2010-06-16 Elixir Pharmaceuticals Inc ANTIVIRAL DRUGS
WO2005108374A1 (en) 2004-04-29 2005-11-17 Fmc Corporation Insecticidal diazole and triazole derivatives
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
EP1796467A4 (en) 2004-09-24 2009-07-01 Janssen Pharmaceutica Nv INHIBITORS IMIDAZO {4,5-B} PYRAZINONE PROTEIN KINASES
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
US7763616B2 (en) 2005-02-16 2010-07-27 Schering Corporation Piperazine-piperidines with CXCR3 antagonist activity
EP1959962A2 (en) 2005-12-16 2008-08-27 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
WO2007125321A2 (en) 2006-04-25 2007-11-08 Astex Therapeutics Limited Purine and deazapurine derivatives as pharmaceutical compounds
US20090082370A1 (en) 2006-04-25 2009-03-26 Neil Thomas Thompson Pharmaceutical Combinations of PK Inhibitors and Other Active Agents
US8227603B2 (en) 2006-08-01 2012-07-24 Cytokinetics, Inc. Modulating skeletal muscle
US20100173930A1 (en) 2006-08-01 2010-07-08 Alex Muci Certain Chemical Entities, Compositions and Methods
US8299248B2 (en) 2006-08-02 2012-10-30 Cytokinetics, Incorporated Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
SI2583970T1 (sl) * 2006-08-02 2016-03-31 Cytokinetics, Inc. Določene kemijske enote, sestavki in postopki, ki obsegajo imidazopirimidine
EP2666777A1 (en) * 2006-08-02 2013-11-27 Cytokinetics, Inc. Certain chemical entities having an imidazo<4,5-b>pyrazin-2(3H)-one core, compositions and methods
NZ576278A (en) 2006-10-19 2011-12-22 Signal Pharm Llc Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors
CL2007002994A1 (es) 2006-10-19 2008-02-08 Wyeth Corp Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
WO2008075007A1 (en) 2006-12-21 2008-06-26 Cancer Research Technology Limited Morpholino-substituted bicycloheteroaryl compounds and their use as anti cancer agents
AU2008206045A1 (en) 2007-01-19 2008-07-24 Ardea Biosciences, Inc. Inhibitors of MEK
EP2139478A4 (en) 2007-03-30 2010-05-05 Cytokinetics Inc CHEMICAL ENTITIES, COMPOSITIONS AND METHODS
EP2018854A1 (en) * 2007-07-27 2009-01-28 Merz Pharma GmbH & Co. KGaA Novel combinations of neramexane for the treatment of neurodegenerative disorders
MX2010008518A (es) 2008-02-04 2010-11-10 Cytokinetics Inc Ciertas entidades quimicas, composiciones y metodos.
US7998976B2 (en) 2008-02-04 2011-08-16 Cytokinetics, Inc. Certain chemical entities, compositions and methods
US20110268729A1 (en) * 2008-07-11 2011-11-03 Bams Abila Treatment of amyotrophic lateral sclerosis by nogo-a-antagonist
CN102264743B (zh) 2008-11-25 2015-02-11 罗彻斯特大学 Mlk抑制剂及其使用方法
EP2228054A1 (en) * 2009-03-13 2010-09-15 ITALFARMACO S.p.A. Riluzole aqueous suspensions
AU2010262970A1 (en) * 2009-06-19 2012-01-12 Knopp Neurosciences, Inc. Compositions and methods for treating amyotrophic lateral sclerosis
AU2013243671B2 (en) 2012-04-02 2017-09-21 Cytokinetics, Inc. Methods for improving diaphragm function
CN104395458A (zh) 2012-04-11 2015-03-04 赛特凯恩蒂克公司 改善对骨骼肌疲劳的抵抗力
EP3137622B1 (en) 2014-04-29 2021-11-24 Cytokinetics, Inc. Methods of reducing decline in vital capacity

Also Published As

Publication number Publication date
CN109316480A (zh) 2019-02-12
EP2731611A4 (en) 2015-02-18
JP2017128610A (ja) 2017-07-27
CA2849213A1 (en) 2013-01-17
KR101951220B1 (ko) 2019-02-22
JP2014520856A (ja) 2014-08-25
AU2012281042A1 (en) 2014-01-30
SG10201605707UA (en) 2016-09-29
IL230391B (en) 2019-03-31
KR20140074270A (ko) 2014-06-17
JP6145946B2 (ja) 2017-06-14
AU2012281042B2 (en) 2016-07-14
US20140243344A1 (en) 2014-08-28
WO2013010015A2 (en) 2013-01-17
NZ619924A (en) 2016-02-26
EA028060B1 (ru) 2017-10-31
WO2013010015A3 (en) 2014-05-15
BR112014000742A2 (pt) 2016-08-23
CN104039148A (zh) 2014-09-10
IN2014DN00200A (enExample) 2015-06-05
EA201490011A1 (ru) 2014-08-29
EA201791043A1 (ru) 2017-09-29
AU2016244263A1 (en) 2016-11-03
HK1197178A1 (en) 2015-01-09
US10272082B2 (en) 2019-04-30
EP2731611B1 (en) 2019-09-18
EP2731611A2 (en) 2014-05-21
ZA201400236B (en) 2014-10-29

Similar Documents

Publication Publication Date Title
PH12014500094A1 (en) Combination als therapy
IN2015DN00450A (enExample)
MX365950B (es) Compuestos de piridazinona y metodos para el tratamiento de la fibrosis quistica.
MX2014004548A (es) Metodos para tratar pacientes pediatricos usando dexmedetomidina.
MX2016005532A (es) Metodos para usar oxido nitrico en un estado de plasma para tratar condiciones medicas y enfermedades.
AU2012229123A8 (en) Methods of treating breast cancer with anthracycline therapy
WO2012093258A3 (en) Irf5- related treatment and screening
MX2015003035A (es) Administracion de inhibidores de acetilcolinesterasa para mitigar la paralisis inducida por neurotoxinas y el bloqueo neuromuscular residual.
SG10201906172XA (en) Regulation of glucose metabolism using anti-cgrp antibodies
MX2015015036A (es) Metodos para mejorar los perfiles de lipidos utilizando atrasentan.
MX2013008715A (es) Uso de (s) -esmolol para controlar la irritacion venosa asociada con el tratamiento de un padecimiento cardiaco.
UA102258C2 (en) Pharmaceutical combination
GB2525517A (en) Topical preparation for pain relief
IN2014DN09990A (enExample)
CA2866819C (en) Method for treating inflammation
MX2016006256A (es) Tratamiento de glaucoma usando laquinimod.
MX2010006724A (es) Regimenes terapeuticos para el tratamiento de desordenes inmunoinflamatorios.
WO2012044963A3 (en) Perfluorocarbons for use in treating pruritus
WO2011163231A3 (en) Combination therapy for the treatment of diabetes
MX2010013790A (es) Composiciones y metodos para tratar inflamacion de corneas.
GEP20186809B (en) Combination therapy agent for treating rhinitis
MX359171B (es) Tratamiento para diabetes tipo i y tipo ii.
PH12014000244A1 (en) Method for the treatment of hypercholesterolemia
UA67100U (ru) Способ лечения переднего эндогенного увеита
UA88418U (ru) Способ лечения хронического рецидивирующего афтозного стоматита